Graft failure is one of the major barriers to the success of allogeneic hematopoietic cell transplantation (HCT) in myelofibrosis (MF). We report our institutional experience with 27 MF patients who underwent HCT using fludarabine-, intravenous BU-and low-dose total body irradiation (FBT)-based reduced-intensity (n = 20) or full-intensity (n = 7) conditioning regimens. Eight patients had prior exposure to JAK1/2 inhibitor therapy; six patients received JAK1/2 inhibitors leading on to HCT and two patients received transplant at the failure of JAK1/2 inhibitor therapy. No adverse impact of JAK1/2 inhibitor therapy was observed on early post-transplant outcomes. All evaluable patients had neutrophil recovery, and no primary graft failure was observed. Cumulative incidence of grades II-IV acute GVHD at day 100 was 48% (95% confidence interval (CI), 29-67%) and chronic GVHD at 2 years was 66% (95% CI, 49-84%). Cumulative incidences of nonrelapse mortality (NRM), relapse and probability of OS at 2 years were: 43% (95% CI, 12-74%), 10% (95% CI, 0-39%) and 56% (95% CI, 28-77%), respectively. FBT-based conditioning regimen has a favorable impact on engraftment; however, further efforts are required to reduce NRM.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is the only available curative modality for patients with myelofibrosis (MF), but is associated with significant mortality and morbidity.
1,2 High risk of graft failure, GVHD and regimen-related toxicities (RRT) result in a higher incidence of nonrelapse mortality (NRM) in MF compared with other hematologic disorders. [3] [4] [5] [6] [7] [8] [9] Conventional conditioning regimens are associated with high NRM, especially in patients older than 50 years.
Fludarabine-and BU-based conditioning regimens are increasingly being used in myeloid malignancies. 10, 11 A further modification of fludarabine-and BU-based regimens was established by investigators from Calgary, Canada, with the addition of 4 Gy total body irradiaiton (TBI), and encouraging outcomes have been reported in acute leukemia. [12] [13] [14] At Princess Margaret Cancer Center, we have used fludarabine-, IV BU-and TBI (FBT)-based conditioning regimens since 2006. To date there are no reported data of FBT regimens in patients with MF, and in this report we describe our institutional experience.
PATIENTS AND METHODS Patients
Since 2007, a total of 27 patients underwent HCT for MF at Princess Margaret Cancer Center with fludarabine, BU and TBI conditioning, and are the subjects of this report. This study was approved by Cancer Registry and Data Access Committee (CRDAC) and Research and Ethics Board of University Health Network (REB #13-6048-AE).
Clinical and laboratory data were retrospectively collected from electronic patient charts and the allogeneic transplant database. All patients included in this study had diagnoses confirmed according to WHO (World Health Organization, 2008) criteria and international working group for myelofibrosis research and treatment (IWG-MRT) consensus criteria. 15, 16 Dynamic International Prognostic Scoring System (DIPSS) and DIPSS plus at the time of HCT were used for disease-specific scoring, and HCT-specific comorbidity index was used for comorbidity scoring. [17] [18] [19] Eight patients had prior exposure to JAK1/2 inhibitor therapy. Two patients received transplant at the failure of JAK1/2 inhibitors, and six patients received JAK1/2 inhibitors leading on to HCT. In patients treated with a combined JAK1/2 inhibitor-HCT strategy, baseline DIPSS and DIPSS plus scores were calculated before the initiation of JAK inhibitor treatment. For the calculation of these scores, transfusion dependency was defined as a requirement of four or more units of packed red cells in 12 weeks before date of scoring, and cytogenetic abnormalities were classified into favorable and unfavorable risk groups based on a previously published report. 20 
Conditioning regimen and GVHD prophylaxis
Patients aged 60 or more years (n = 15) and younger patients with significant comorbidities (n = 5) were prepared by a reducedintensity regimen (FBT200) that consists of intravenous fludarabine (F), 30 mg/m 2 /day on days − 5 to day − 2 (total 120 mg/m 2 ), and intravenous BU, 3.2 mg/kg/day on days − 3 and day − 2 (total 6.4 mg/kg) and 200 cGy TBI (T200) given on day − 1.
Younger patients without significant comorbidities (n = 7) were prepared with a full-intensity conditioning (FIC) regimen (FBT400) that consists of intravenous fludarabine (F), 50 mg/m 2 /day on days − 5 to day − 2 (total 200 mg/m target a serum trough level of 200-400 μg/L. In the absence of GVHD, cyclosporine was tapered over 2-3 weeks after day +90. Mycophenolate was started on day 0 at a dose of 15 mg/kg per dose p.o./i.v. three times daily, and was given for 28 days. Four out of eight HLA-matched unrelated donor (URD) transplants received in vivo T-cell depletion (TCD) with lowdose alemtuzumab as part of the institutional protocol of that time. In addition, all partially matched URD transplants (n = 3) received either lowdose alemtuzumab (n = 2) or rabbit antithymocyte globulin (n = 1). Alemtuzumab was given as a single dose of 30 mg subcutaneously a day before conditioning regimen (day − 6). Rabbit antithymocyte globulin (thymoglobulin) was given at a dose of 4.5 mg/kg divided over 3 days.
Supportive care
All patients received antibiotic prophylaxis until the ANC had reached 41 × 10 9 /L. Pneumocystis prophylaxis was given with oral co-trimoxazole or inhaled pentamidine for 1 year. Acyclovir was used for 28 days in matched related donor transplants, or 3 months in URD transplants as HSV prophylaxis. URD transplant recipients also received antifungal prophylaxis with either itraconazole or posaconazole for 3 months. A preemptive therapy strategy was used against CMV reactivation based on pp65 antigenemia until 2010, and CMV PCR after that.
Definitions and evaluation of responses
Patients who survived more than 14 days were evaluable for assessment of hematologic recovery. Dates of platelet and neutrophil recovery were defined as the first of 3 consecutive days of unsupported platelet count 420 × 10 9 /L and ANC of more than 0.5 × 10 9 /L, respectively. Primary graft failure was defined as the failure to recover ANC by day +35 as reported previously. 21 DNA PCR for donor chimerism was done on unsorted peripheral blood cells on days 30, 60 and 120 in reduced-intensity conditioning (RIC) recipients routinely, and subsequently according to clinical needs. Donor cells ⩾ 90% were considered as predominantly donor chimerism, and o90 percent as mixed chimerism. Sustained donor engraftment was defined as sustained donor-derived count recovery with donor chimerism of at least 90% (both units combined). 22 RRT and hepatic veno-occlusive disease were defined as per Bearman's and Baltimore criteria, respectively. 23, 24 Acute and chronic GVHD were graded according to modified Gluckberg's and NIH consensus criteria. 25, 26 Bacterial and viral infections were defined as culture or PCR positivity in appropriate clinical settings, and invasive fungal infections were defined as per EORTC/MSG criteria. 27 All patients had a pre-HCT BM examination done within 2 weeks before transplant. Post-HCT BM examinations were done at day +60, day +180, 12 months and yearly afterward until resolution of fibrosis. Disease response was assessed at 6 months, 12 months and yearly afterwards using IWG-MRT 2006 consensus criteria. 28 During the preparation of this manuscript, revised response criteria were published as a consensus report of IWG-MRT and European Leukemia Net (ELN). 29 Therefore, response was also assessed according to the new revised criteria of IWG-MRT and ELN.
Statistical methods
Categorical variables were summarized with counts and percentages and continuous variables with medians and ranges. The probabilities of OS and PFSs were calculated by Kaplan-Meier method. Probabilities of relapse and NRM were generated with cumulative incidence method for competing end points. Times taken to reach various hematologic end points also were calculated using cumulative incidence method with death as a competing end point, and differences between groups were calculated using Gray's method. SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and the open source statistical software R version 15.2 were used to perform statistical analyses.
RESULTS

Baseline characteristics
A total of 27 patients received HCT with these regimens between 2007 and 2013. Baseline characteristics are listed in Table 1 . Median age at transplantation was 61 (range, 30-70) years. Twenty (74%) patients received RIC and seven (26%) full-intensity conditioning regimens. The source of hematopoietic cells was peripheral blood in 26 patients (96%), and one patient received Figure 1 . Patients with a pre-transplant spleen size ⩾ 10 cm below costal margin had significantly longer times for blood cell count recovery when compared with patients with o10 cm below costal margin or asplenic ( Table 2) .
Serial (1 month, 2 month and 4 month) chimerism data were available in 18 patients. Sixteen (89%) patients had sustained predominantly donor engraftment at 4 months. This include 13 (72%) patients with donor chimerism 495% and 3 (17%) patients with 90-95%. There were no differences between these two groups in terms of treatment response at 6 months or transfusion requirement. Two patients (11%) experienced decreasing donor chimerism after engraftment. Among these, one patient was successfully rescued by withdrawing prophylactic immunosuppression, and the other patient developed clinical relapse.
RRT, infectious complications and GVHD Details of transplant outcomes are listed in Table 3 . Stomatitis was the most common RRT and was seen in 52% with grade 2, but none had grade 3 or 4 severity. Among five patients with hepatic toxicities, four satisfied the Baltimore criteria of veno-occlusive disease. One patient died of veno-occlusive disease on day +11. Unexplained transient delirium (grade 2 central nervous system toxicity) was observed in one patient.
Among 18 CMV-seropositive recipients, 13 (72%) developed CMV reactivation in the first 1 year. In 11 patients, reactivation occurred within day +100. One patient developed CMV retinitis and another patient developed CMV gastritis.
Nine patients developed grades II-IV acute GVHD, this included two patients with grade III and one patient with grade IV acute GVHD. Cumulative incidence of grades II-IV acute GVHD at day 100 was 48% (95% confidence interval (CI), 29-67%). Eighteen patients developed chronic GVHD and this included 1 patient with mild, 5 patients with moderate and 12 patients with severe grades according to the NIH criteria. Cumulative incidence of chronic GVHD at 2 years was 66% (95% CI, 49-84%).
NRM, relapse and survival The cumulative incidences of NRM at day 100, 1 year and 2 years were 7% (95% CI, 0-18%), 23% (95% CI, 7-39%) and 43% (95% CI, 12-74%), respectively. The cumulative incidences of relapse or progression at 1 and 2 years were 4% (95% CI, 0-14%) and 10% (95% CI, 0-39%), respectively (Figure 2a) .
Two patients relapsed at 6 and 19 months after HCT. The first patient who received BM from a matched sibling donor developed decreasing donor chimerism before clinical and hematologic manifestations of relapse. This patient progressed despite donor lymphocyte infusion (1 × 10 7 CD3 + cells/kg × 1 dose), and eventually was started on ruxolitinib. At 13 months after relapse, she remains alive with a very good symptom control with ruxolitinib. The second patient whose post-HCT period was complicated by severe chronic GVHD achieved CR status at 11 months, and relapsed at 19 months with recurrence of systemic symptoms, splenomegaly and transfusion dependency. At relapse, she was started on an investigational JAK1 inhibitor INCB39110, but had a rapid progression of disease and died 28 months after transplant.
The probability of OS at 1 and 2 years was 77% (56-89%) and 56% (28-77%), respectively (Figure 2b) . No patient-, disease-or transplant-related variables were found to have significant impact on survival in univariable analysis (data not shown). Owing to Not evaluable due to missing cytogenetic information; however, these three patients had at least intermediate 2 DIPSS score. c Grading of myelofibrosis is according to the European classification. 40 limited sample size, a multivariable analysis was not performed. At the last follow-up, 10 patients had died. Causes of death were: GVHD in five, infections in two, hepatic veno-occlusive disease in one, multiorgan failure in one and relapse in one patient. The probability of PFS at 1 and 2 years was 73% (52-86%) and 46% (20-68%), respectively.
Disappearance of constitutional symptoms, leukoerythroblastic blood picture, splenomegaly and BM fibrosis No documented persistence of systemic symptoms was observed in any patients during the post-transplant period, except during relapses. Disappearance of leukoerythroblastic blood picture occurred in 26 (96%) at a median of 0.7 months (range, 0-20).
Disappearance of palpable splenomegaly was documented in 35 and 60% of patients at 6 and 12 months, respectively. Resolution of fibrosis was documented in 40 and 75% of evaluable patients at 6 and 12 months, respectively. A separate analysis of patients who survived 6 months showed no correlation between resolution of fibrosis at 6 months and PFS or OS.
JAK2 V617F mutation status after HCT Fifteen (56%) patients were JAK2 positive before HCT. Among these, 13 patients had mutation analysis available after HCT. In all, except one (92%), JAK2 PCR became negative within 60 days of HCT. Among this, one patient experienced recurrence of JAK2 mutation 20 months after HCT during clinical relapse. One patient had low positive level of JAK2 mutation at day +30 after HCT, Table 4 . When IWG-MRT criteria were applied, the best response was either clinical improvement or stable disease in 7 out of 15 patients who were alive and progression free at 1 year. Some of these patients did not meet the criteria for CR or PR because of isolated thrombocytopenia or anemia. This included two patients who are long-term survivors of 5 years or more, and one of them remains in clinical improvement even after 5 years because of platelet count persisting in 50-100 × 10 9 /L range. When the recently published IWG-MRT and ELN criteria were applied, three out of seven patients in the stable disease/clinical improvement category have moved to PR status as they had resolution of fibrosis and splenomegaly. There was no difference in the number of patients achieving CR status.
Outcomes of patients with prior exposure to JAK1/2 inhibitor therapy Six patients received JAK1/2 inhibitor therapy (ruxolitinib, four patients; momelitinib, 30 two patients) leading on to HCT, and their characteristics are summarized in Table 5 . In all these patients, a strategy of gradual tapering of JAK1/2 inhibitor was used without any steroid cover. The tapering was started 5-6 days before the planned start date of conditioning regimen and completed 24 h before the start of conditioning regimen. None of these patients developed any cytokine-related 'withdrawal symptoms' or any other adverse events. There was no increase in RRT, and all these patients had hematopoietic recovery. However, 4/4 (100%) CMVseropositive recipients developed CMV reactivation, and two had developed mucocutaneous HSV lesions. None developed CMV disease or disseminated HSV disease. One patient developed probable invasive fungal pneumonia and two patients developed BK virus cystitis.
There was no apparent increase in the incidence of acute GVHD, and no patient had developed grades 3/4 acute GVHD. Two patients developed severe grade chronic GVHD and one of these patients died of its complications at 21 months.
DISCUSSION
Even with modern conditioning regimens, graft failure is one of the major barriers to successful outcomes of HCT in MF. In a multicenter prospective trial using fludarabine-and BU-based RIC in MF (n = 102), primary graft failure was reported in 2%. However, an additional 11% of patients required a 'stem cell boost' presumably due to poor graft function. 7 Similarly, in a phase II clinical trial of MPD-RC consortium using fludarabine and melphalan, a high rate of graft failure (26%) was observed in URD setting. 31 A third study reported lack of neutrophil engraftment in 14% of patients, and use of DLI in 21% of the patients in the RIC group due to incomplete donor chimerism. 5 In our study, we have used fludarabine-, BU-and TBI-based fullintensity conditioning or RIC. In these regimens, TBI was expected to reduce the incidence of graft failure and no primary graft failure was observed. Similarly, the cumulative incidence of relapse at 2 years, 10% (95% CI, 0-39%), also was lower than what was observed in other recent reports 7, 32 However, the incidences of acute and chronic GVHD in our cohort were higher than those in other reports. Severe chronic GVHD (NIH grading) was present in 48% of patients and accounted for 5 out of 10 deaths, offsetting the favorable effect of regimen on engraftment and relapse.
The possible causes of a higher incidence of chronic GVHD include lower use of TCD in these patients compared with that of patients in other published reports. TCD was reported in 53% in recently published CIBMTR registry analysis, 32 and 100% in a multicenter phase II trial from Germany. 7 In our cohort, only 26% of patients received TCD, although 41% of patients had either matched or partially mismatched URDs. Another possible cause for higher incidence of GVHD is the use of TBI, which in higher doses is reported to be associated with increased incidence of acute GVHD. 33 However, lower doses (similar to what was used in our cohort) in combination with TCD are not associated with increased risk of GVHD. 13 We have recently amended our institutional policy to use TCD in all URDs.
Regimen-related hepatotoxicity is a major complication in MF patients undergoing HCT. MF patients are at a higher risk of hepatotoxicity as previously reported by Seattle group and ourselves. 9, 34 With this regimen, the risk of hepatotoxicity, although lower than our previous experience, is still higher compared with other myeloid malignancies.
Recently, there has been interest in the use of JAK1/2 inhibitors in the transplant setting with the goal of reducing NRM. Certain properties of JAK1/2 inhibitors such as reduction in splenomegaly, and improvement of performance status and overall well-being are particularly attractive in the pre-transplant setting. [35] [36] [37] On the other hand, immunomodulatory effects of JAK inhibitors persisting after HCT can have mixed effects. They can theoretically reduce acute GVHD by downregulation of cytokines, but at the same time potentially impair antiviral immunity by inducing dendritic cell dysfunction. 38 How much of these effects persist in the post-HCT phase is currently unknown, as data on use of JAK inhibitors in the transplant setting have just started to emerge. Three groups have recently published their experience in this strategy. One group reported serious adverse effects during ruxolitinib withdrawal including unexpected tumor lysis syndrome and cardiogenic shock. 39 However, two other groups did not observe any significant adverse effects during withdrawal; in addition, there was a favorable effect on splenomegaly and constitutional symptoms with ruxolitinib pretreatment. 40, 41 We have used this approach in six patients at our center. In this report, we have shown that this strategy is feasible. By using a tapering schedule before transplant, we did not observe any rebound symptoms or unexpected toxicities. There was no adverse impact on neutrophil or platelet recoveries and none of these patients had severe acute GVHD. On the basis of small numbers, it is difficult to say whether the incidence of viral infections is higher in these patients. These observations should only be considered preliminary at present, and the overall safety and efficacy of this approach is being addressed in on-going prospective trials. This approach should ideally be used in the setting of clinical trials, or at experienced centers familiar with the use of JAK1/2 inhibitors for MF patients. The biology of engraftment in MF is not fully understood. Platelet count recovery was the most delayed, and this effect was more prominent in patients with larger pre-transplant spleen size. It is not clear whether this was purely due to peripheral destruction or not. Favorable effect of pre-HCT splenectomy on engraftment, as reported by other groups, may support this hypothesis. 7, 42, 43 However, we have observed delayed platelet and red cell recovery even after regression of clinical splenomegaly, which may suggest that factors other than peripheral destruction also could be contributing. The role of JAK inhibitors in the pre-HCT setting, owing to their salutary effect on splenomegaly, can be relevant here. However, we have not observed any survival difference based on spleen size, although owing to the small size of cohort, definite conclusions cannot be drawn.
The IWG-MRT 2006 criteria are being widely used in response assessment in clinical trials in MF patients, but its utility has not been validated in the BMT setting. In our study, we found that even though HCT is considered a curative therapy, the criteria for CR/PR are not met even in some long-term survivors, and the best response achieved was clinical improvement in a large proportion of patients. This was because of lack of complete platelet recovery and/or red cell recovery even in those who had resolution of marrow fibrosis, splenomegaly and disappearance of leukoerythroblastic blood picture. Recently, revised criteria have been reported by the joint consensus report from IWG-MRT and ELN. A comparison of response rate according to the old IWG-MRT criteria and the revised IWG-MRT/ELN criteria shows that the revised criteria are more meaningful in the HCT setting, as they capture the disease-modifying properties of the transplant better than the old criteria. The impact of these different responses on survival is not known at present, and needs to be studied in the future.
At present, the role of JAK2 V671F mutation monitoring in the posttransplant setting is not established. The value of JAK2 allele burden as a surrogate marker for malignant clone was previously evaluated in a study from Germany. 44 This study showed correlation between presence of mutation and clinical outcomes in the post-transplant setting. One patient in our study, who was weakly positive for JAK mutation in the immediate post-transplant period, became strongly positive 4 months after transplant, and this was accompanied by decreasing donor chimerism. After withdrawal of immunosuppression, this patient became JAK mutation negative and attained full donor chimerism. Therefore, monitoring can be useful in some patients. It is noteworthy that JAK2 V617F mutation is not considered as a primary event in the pathogenesis of myeloproliferative neoplasm; hence, better strategies for monitoring of malignant clone in the post-HCT setting are needed in future.
In summary, fludarabine, IV BU and TBI regimens have a favorable impact on engraftment in patients with MF; however, NRM remains high and further effort is needed to reduce this. Whether routine use of TCD and/or inclusion of JAK1/2 inhibitors in the pre-HCT phase help in reduction of NRM remains to be seen in prospective trials.
